Researchers at Queen Mary University of London have validated a non-invasive brush biopsy test capable of detecting oral cancer within one hour. Published in the journal Biomarker Research, the study found the test could eliminate the need for over 90% of traditional scalpel biopsies, which are often painful and carry risks of infection or structural damage to the mouth.
How the new brush biopsy test functions
The diagnostic tool, known as qMIDS-V3, works by analyzing a simple brush swab of the mouth. Unlike traditional methods that require a surgeon to cut into tissue, this test uses a multigene assay to identify oral squamous cell carcinoma (OSCC) from superficial cells. According to the research team, the test performance is highly comparable to its predecessor, qMIDS-V2, which required a 1mm microbiopsy. Professor Muy-Teck Teh, lead researcher at Queen Mary University of London, noted that the biological signal captured by the four genes is consistent enough to be detected without removing any tissue.
The study is the largest of its kind, involving more than 1,000 samples collected from 545 patients.
Why current diagnostic pathways face criticism
Current diagnostic pathways for oral cancer often lead to over-referral and inefficiency. Data from a 10-year audit in the UK revealed a 450% increase in two-week wait referrals, yet these were accompanied by a 50% decrease in actual cancer detection rates. The audit showed that between 92.5% and 99.5% of referred patients were cancer-free, with the vast majority remaining healthy at their five-year follow-up. By implementing a rapid triage test like qMIDS-V3, clinicians could significantly reduce the burden on patients who do not require invasive procedures.
The impact on early-stage detection
Early diagnosis is vital for survival, yet more than half (53%) of all mouth cancers are diagnosed at stage IV, the most advanced level. The qMIDS-V3 test offers a critical advantage for long-term surveillance of patients with potentially malignant disorders. Because the procedure is non-invasive and repeatable, doctors can monitor high-risk patients systematically. This allows for the detection of malignant transformation at a much earlier stage, when treatment outcomes are statistically better.
Pro Tip: Risk factors to monitor
Clinicians and patients should remain vigilant for symptoms, particularly those with known risk factors. These include tobacco use, alcohol, HPV infection, and sun damage.
Frequently Asked Questions
How soon could this test be available for clinical use?
Queen Mary University of London is currently seeking a commercial partner to facilitate development. With an appropriate partner, researchers estimate the test could be in clinical use within two years.
Is the new brush test as accurate as a scalpel biopsy?
According to the study published in Biomarker Research, the brush swab test performance is highly comparable to the microbiopsy method, despite requiring no tissue removal.
Why are scalpel biopsies considered problematic?
Scalpel biopsies can be extremely painful, particularly when performed on the tongue, which is the most common site for oral cancer. The procedure can also cause infections and damage the underlying tooth or bone structure, often discouraging both patients and clinicians from repeating the test when necessary.
Have questions about oral health screenings? Consult your local dental professional or physician. For more updates on medical breakthroughs, subscribe to our newsletter or explore our archive of health research articles.